Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies

P. Crilley, H. Lazarus, D. Topolsky, N. Ciobanu, R. J. Creger, R. M. Fox, S. I. Bulova, D. C. Shina, Rasim A. Gucalp, B. W. Cooper, W. Soegiarso, M. Styler, I. Brodsky

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Most bone marrow transplantation preparative regimens use total body irradiation as one component. Recently, however, two non-total body irradiation containing autologous bone marrow transplantation preparative regimens have been evaluated in patients with lymphoid malignancies. The first regimen consisted of carmustine, etoposide, and cisplatin; some patients also received involved-field radiotherapy to sites of prior disease. Of the 79 patients with relapsed or refractory lymphoma who participated in this study, 57 (72%) achieved a complete remission and 40 (51%) remain in complete remission. Treatment-related deaths occurred in five patients (6%). The second preparative regimen evaluated consisted of busulfan, etoposide, and cyclophosphamide and included 21 patients with Hodgkin's lymphoma, non- Hodgkin's lymphoma, or acute lymphocytic leukemia. Sixteen patients (76%) achieved complete remission and 12 (57%) remain disease free. The regimen- related mortality rate in this study was 14%. The three treatment-related deaths were all due to pulmonary toxicity. The results of these clinical trials indicate that both the carmustine/etoposide/cisplatin regimen and the busulfan/etoposide/cyclophosphamide regimen are effective in treating lymphoid malignancies. Treatment-related toxicities and deaths are significant, but not prohibitive. Accordingly, these new preparative regimens deserve further evaluation in the treatment of patients with lymphoma or leukemia.

Original languageEnglish (US)
Pages (from-to)50-54
Number of pages5
JournalSeminars in Oncology
Volume20
Issue number4 SUPPL. 4
StatePublished - 1993
Externally publishedYes

Fingerprint

Carmustine
Busulfan
Etoposide
Cyclophosphamide
Cisplatin
Transplantation
Neoplasms
Bone Marrow Transplantation
Lymphoma
Autologous Transplantation
Whole-Body Irradiation
Therapeutics
Hodgkin Disease
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Non-Hodgkin's Lymphoma
Leukemia
Radiotherapy
Clinical Trials
Lung
Mortality

ASJC Scopus subject areas

  • Oncology

Cite this

Crilley, P., Lazarus, H., Topolsky, D., Ciobanu, N., Creger, R. J., Fox, R. M., ... Brodsky, I. (1993). Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies. Seminars in Oncology, 20(4 SUPPL. 4), 50-54.

Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies. / Crilley, P.; Lazarus, H.; Topolsky, D.; Ciobanu, N.; Creger, R. J.; Fox, R. M.; Bulova, S. I.; Shina, D. C.; Gucalp, Rasim A.; Cooper, B. W.; Soegiarso, W.; Styler, M.; Brodsky, I.

In: Seminars in Oncology, Vol. 20, No. 4 SUPPL. 4, 1993, p. 50-54.

Research output: Contribution to journalArticle

Crilley, P, Lazarus, H, Topolsky, D, Ciobanu, N, Creger, RJ, Fox, RM, Bulova, SI, Shina, DC, Gucalp, RA, Cooper, BW, Soegiarso, W, Styler, M & Brodsky, I 1993, 'Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies', Seminars in Oncology, vol. 20, no. 4 SUPPL. 4, pp. 50-54.
Crilley, P. ; Lazarus, H. ; Topolsky, D. ; Ciobanu, N. ; Creger, R. J. ; Fox, R. M. ; Bulova, S. I. ; Shina, D. C. ; Gucalp, Rasim A. ; Cooper, B. W. ; Soegiarso, W. ; Styler, M. ; Brodsky, I. / Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies. In: Seminars in Oncology. 1993 ; Vol. 20, No. 4 SUPPL. 4. pp. 50-54.
@article{69d362d2508d4ce192c23b02e572d4e4,
title = "Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies",
abstract = "Most bone marrow transplantation preparative regimens use total body irradiation as one component. Recently, however, two non-total body irradiation containing autologous bone marrow transplantation preparative regimens have been evaluated in patients with lymphoid malignancies. The first regimen consisted of carmustine, etoposide, and cisplatin; some patients also received involved-field radiotherapy to sites of prior disease. Of the 79 patients with relapsed or refractory lymphoma who participated in this study, 57 (72{\%}) achieved a complete remission and 40 (51{\%}) remain in complete remission. Treatment-related deaths occurred in five patients (6{\%}). The second preparative regimen evaluated consisted of busulfan, etoposide, and cyclophosphamide and included 21 patients with Hodgkin's lymphoma, non- Hodgkin's lymphoma, or acute lymphocytic leukemia. Sixteen patients (76{\%}) achieved complete remission and 12 (57{\%}) remain disease free. The regimen- related mortality rate in this study was 14{\%}. The three treatment-related deaths were all due to pulmonary toxicity. The results of these clinical trials indicate that both the carmustine/etoposide/cisplatin regimen and the busulfan/etoposide/cyclophosphamide regimen are effective in treating lymphoid malignancies. Treatment-related toxicities and deaths are significant, but not prohibitive. Accordingly, these new preparative regimens deserve further evaluation in the treatment of patients with lymphoma or leukemia.",
author = "P. Crilley and H. Lazarus and D. Topolsky and N. Ciobanu and Creger, {R. J.} and Fox, {R. M.} and Bulova, {S. I.} and Shina, {D. C.} and Gucalp, {Rasim A.} and Cooper, {B. W.} and W. Soegiarso and M. Styler and I. Brodsky",
year = "1993",
language = "English (US)",
volume = "20",
pages = "50--54",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 4",

}

TY - JOUR

T1 - Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies

AU - Crilley, P.

AU - Lazarus, H.

AU - Topolsky, D.

AU - Ciobanu, N.

AU - Creger, R. J.

AU - Fox, R. M.

AU - Bulova, S. I.

AU - Shina, D. C.

AU - Gucalp, Rasim A.

AU - Cooper, B. W.

AU - Soegiarso, W.

AU - Styler, M.

AU - Brodsky, I.

PY - 1993

Y1 - 1993

N2 - Most bone marrow transplantation preparative regimens use total body irradiation as one component. Recently, however, two non-total body irradiation containing autologous bone marrow transplantation preparative regimens have been evaluated in patients with lymphoid malignancies. The first regimen consisted of carmustine, etoposide, and cisplatin; some patients also received involved-field radiotherapy to sites of prior disease. Of the 79 patients with relapsed or refractory lymphoma who participated in this study, 57 (72%) achieved a complete remission and 40 (51%) remain in complete remission. Treatment-related deaths occurred in five patients (6%). The second preparative regimen evaluated consisted of busulfan, etoposide, and cyclophosphamide and included 21 patients with Hodgkin's lymphoma, non- Hodgkin's lymphoma, or acute lymphocytic leukemia. Sixteen patients (76%) achieved complete remission and 12 (57%) remain disease free. The regimen- related mortality rate in this study was 14%. The three treatment-related deaths were all due to pulmonary toxicity. The results of these clinical trials indicate that both the carmustine/etoposide/cisplatin regimen and the busulfan/etoposide/cyclophosphamide regimen are effective in treating lymphoid malignancies. Treatment-related toxicities and deaths are significant, but not prohibitive. Accordingly, these new preparative regimens deserve further evaluation in the treatment of patients with lymphoma or leukemia.

AB - Most bone marrow transplantation preparative regimens use total body irradiation as one component. Recently, however, two non-total body irradiation containing autologous bone marrow transplantation preparative regimens have been evaluated in patients with lymphoid malignancies. The first regimen consisted of carmustine, etoposide, and cisplatin; some patients also received involved-field radiotherapy to sites of prior disease. Of the 79 patients with relapsed or refractory lymphoma who participated in this study, 57 (72%) achieved a complete remission and 40 (51%) remain in complete remission. Treatment-related deaths occurred in five patients (6%). The second preparative regimen evaluated consisted of busulfan, etoposide, and cyclophosphamide and included 21 patients with Hodgkin's lymphoma, non- Hodgkin's lymphoma, or acute lymphocytic leukemia. Sixteen patients (76%) achieved complete remission and 12 (57%) remain disease free. The regimen- related mortality rate in this study was 14%. The three treatment-related deaths were all due to pulmonary toxicity. The results of these clinical trials indicate that both the carmustine/etoposide/cisplatin regimen and the busulfan/etoposide/cyclophosphamide regimen are effective in treating lymphoid malignancies. Treatment-related toxicities and deaths are significant, but not prohibitive. Accordingly, these new preparative regimens deserve further evaluation in the treatment of patients with lymphoma or leukemia.

UR - http://www.scopus.com/inward/record.url?scp=0027290608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027290608&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 50

EP - 54

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4 SUPPL. 4

ER -